Global pharma activity in China intensified as AbbVie struck a deal with Zelgen Biopharmaceuticals for a DLL3-targeted clinical-stage T cell engager to develop in China, while Hutchmed secured NMPA acceptance and priority review for fanregratinib—an FGFR-targeted therapy for intrahepatic cholangiocarcinoma—based on a single phase II registration study. Both moves highlight China’s evolving regulatory openness to accelerated oncology pathways and the continued interest of multinational and domestic firms to localize development and commercialization strategies for high‑need tumor types.